See more : Shenzhen EXC-LED Technology Co.Ltd (300889.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Pharming Group N.V. (PHARM.AS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharming Group N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- Texture Maker Enterprise Co., Ltd (6963.TWO) Income Statement Analysis – Financial Results
- Darshan Orna Limited (DARSHANORNA.BO) Income Statement Analysis – Financial Results
- Cervus Equipment Corporation (CERV.TO) Income Statement Analysis – Financial Results
- Fielmann Aktiengesellschaft (FLMNY) Income Statement Analysis – Financial Results
- PPD, Inc. (PPD) Income Statement Analysis – Financial Results
Pharming Group N.V. (PHARM.AS)
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 245.32M | 205.62M | 189.85M | 228.39M | 189.33M | 154.58M | 107.52M | 16.69M | 11.84M | 25.76M | 9.45M | 14.04M | 3.89M | 762.07K | 1.57M | 924.35K | 1.01M | 194.01K | 479.68K |
| Cost of Revenue | 25.21M | 17.56M | 20.18M | 25.34M | 23.92M | 25.37M | 14.93M | 4.93M | 5.25M | 4.17M | 1.54M | 5.64M | 4.58M | 121.03K | 0.00 | 0.00 | 36.90M | 0.00 | 6.17M |
| Gross Profit | 220.10M | 188.06M | 169.67M | 203.06M | 165.41M | 129.20M | 92.59M | 11.77M | 6.59M | 21.60M | 7.92M | 8.39M | -688.23K | 641.04K | 1.57M | 924.35K | -35.90M | 194.01K | -5.69M |
| Gross Profit Ratio | 89.72% | 91.46% | 89.37% | 88.91% | 87.37% | 83.59% | 86.11% | 70.50% | 55.67% | 83.82% | 83.75% | 59.79% | -17.71% | 84.12% | 100.00% | 100.00% | -3,568.26% | 100.00% | -1,187.16% |
| Research & Development | 68.91M | 52.53M | 67.18M | 41.46M | 31.78M | 33.04M | 22.38M | 16.18M | 15.50M | 14.18M | 14.13M | 25.59M | 17.92M | 28.14M | 35.14M | 29.03M | 27.83M | 11.10M | 10.57M |
| General & Administrative | 80.68M | 46.02M | 35.30M | 14.42M | 21.19M | 13.98M | 7.17M | 4.88M | 4.09M | 4.04M | 3.48M | 4.56M | 4.23M | 4.41M | 5.11M | 4.33M | 4.12M | 3.71M | 0.00 |
| Selling & Marketing | 6.82M | 85.80M | 56.75M | 55.55M | 44.71M | 39.51M | 37.70M | 3.19M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.73M |
| SG&A | 87.50M | 131.82M | 92.05M | 69.97M | 65.90M | 53.49M | 44.86M | 8.07M | 5.28M | 4.04M | 3.48M | 4.56M | 4.23M | 4.41M | 5.11M | 4.33M | 4.12M | 3.71M | 2.73M |
| Other Expenses | 69.08M | -14.52M | -2.50M | 9.54M | -487.27K | -684.00K | -790.00K | -335.00K | -147.00K | -105.00K | -106.00K | -2.06M | 843.00K | -15.17M | 5.71M | 8.07M | -23.62M | -1.64M | 2.40M |
| Operating Expenses | 225.49M | 169.83M | 156.72M | 120.97M | 97.19M | 85.74M | 66.30M | 23.91M | 20.62M | 18.10M | 17.46M | 29.82M | 23.25M | 31.81M | 41.18M | 36.12M | -440.32K | 23.52M | 16.15M |
| Cost & Expenses | 250.70M | 187.39M | 176.91M | 146.31M | 121.11M | 111.12M | 81.23M | 28.83M | 25.87M | 22.26M | 19.00M | 35.47M | 27.82M | 31.93M | 41.18M | 36.12M | 36.46M | 23.52M | 22.32M |
| Interest Income | 3.53M | 85.00K | 14.23M | 769.95K | 1.13M | 20.59K | 3.60K | 5.26K | 130.10K | 218.88K | 0.00 | -4.54M | -0.66 | -792.66K | 610.35K | 2.81M | 4.82M | 2.91M | 814.87K |
| Interest Expense | 5.96M | 5.36M | 5.92M | 6.40M | 13.35M | 16.37M | 21.28M | 3.77M | 135.57K | 212.80K | 3.29M | 3.43M | 276.07K | 6.67M | 11.87M | 1.87M | 1.94M | 1.71M | 10.66K |
| Depreciation & Amortization | 15.93M | 13.19M | 19.61M | 8.31M | 5.80M | 7.50M | 4.10M | 795.09K | -716.11K | 218.88K | -6.29M | -2.87M | -155.53K | 12.24M | 6.60M | 1.98M | 2.05M | 1.59M | 1.23M |
| EBITDA | 9.88M | 33.53M | 48.78M | 92.11M | 71.46M | 50.98M | -39.81M | -13.88M | -14.75M | 3.72M | -15.83M | -25.97M | -24.13M | -46.46M | -33.29M | -33.69M | -47.90M | -21.17M | -19.86M |
| EBITDA Ratio | 4.03% | 15.86% | 24.52% | 40.33% | 39.83% | 32.98% | -37.03% | -83.54% | -124.58% | 14.43% | -167.55% | -185.00% | -620.91% | -6,095.99% | -2,120.26% | -3,645.18% | -4,760.87% | -10,671.47% | -4,140.99% |
| Operating Income | -4.88M | 18.23M | 27.84M | 82.09M | 68.23M | 43.46M | 26.29M | -12.14M | -14.03M | 3.50M | -9.54M | -23.09M | -23.98M | -58.69M | -39.90M | -41.02M | -35.90M | -23.80M | -21.84M |
| Operating Income Ratio | -1.99% | 8.87% | 14.66% | 35.94% | 36.03% | 28.12% | 24.45% | -72.70% | -118.53% | 13.58% | -100.99% | -164.52% | -616.91% | -7,701.75% | -2,540.88% | -4,437.80% | -3,568.26% | -12,267.39% | -4,553.34% |
| Total Other Income/Expenses | -7.13M | -3.25M | -4.76M | -18.33M | -15.94M | -37.01M | -129.09M | -6.31M | 4.07M | -9.89M | -5.52M | -1.00M | 852.83K | -21.96M | -5.55M | 4.54M | 4.34M | -678.38K | 689.32K |
| Income Before Tax | -12.01M | 14.99M | 22.03M | 47.47M | 52.29M | 980.32K | -107.25M | -18.44M | -10.89M | -7.01M | -20.80M | -31.86M | -23.13M | -80.65M | -45.45M | -36.48M | -52.32M | -24.48M | -21.15M |
| Income Before Tax Ratio | -4.90% | 7.29% | 11.60% | 20.78% | 27.62% | 0.63% | -99.75% | -110.48% | -91.96% | -27.22% | -220.05% | -227.01% | -594.97% | -10,583.43% | -2,894.53% | -3,946.54% | -5,201.16% | -12,617.06% | -4,409.64% |
| Income Tax Expense | -1.46M | 1.31M | 6.76M | 6.83M | 11.74M | -27.61M | -11.33M | 3.77M | 851.68K | -6.08K | 10.83M | 6.31M | -1.15M | -5.69M | 481.40K | 4.07M | -402.41K | -67.31K | 636.48K |
| Net Income | -10.55M | 13.67M | 16.00M | 37.75M | 40.54M | 28.59M | -95.92M | -18.44M | -10.89M | -7.01M | -20.80M | -31.86M | -22.17M | -74.97M | -45.93M | -36.48M | -51.92M | -24.41M | -21.15M |
| Net Income Ratio | -4.30% | 6.65% | 8.43% | 16.53% | 21.41% | 18.50% | -89.22% | -110.48% | -91.96% | -27.22% | -220.05% | -227.01% | -570.32% | -9,837.18% | -2,925.18% | -3,946.54% | -5,161.16% | -12,582.36% | -4,409.64% |
| EPS | -0.01 | 0.02 | 0.02 | 0.05 | 0.05 | 0.04 | -0.15 | -0.04 | -0.02 | -0.01 | -0.08 | -0.35 | -0.37 | -2.24 | -3.14 | -3.16 | -4.54 | -2.25 | -2.12 |
| EPS Diluted | -0.01 | 0.02 | 0.02 | 0.04 | 0.05 | 0.04 | -0.15 | -0.04 | -0.02 | -0.01 | -0.08 | -0.35 | -0.37 | -2.24 | -3.14 | -3.16 | -4.54 | -2.25 | -2.12 |
| Weighted Avg Shares Out | 821.28M | 883.93M | 876.44M | 853.42M | 841.90M | 816.91M | 625.52M | 519.23M | 510.85M | 495.12M | 268.26M | 91.91M | 59.22M | 33.54M | 14.63M | 11.54M | 11.45M | 10.85M | 9.97M |
| Weighted Avg Shares Out (Dil) | 843.25M | 883.93M | 876.44M | 853.42M | 841.90M | 816.91M | 625.52M | 519.23M | 510.85M | 495.12M | 268.26M | 91.91M | 59.22M | 33.54M | 14.63M | 11.54M | 11.45M | 10.85M | 9.97M |
Source: https://incomestatements.info
Category: Stock Reports